We carried out the first systematic review assessing if assessment of blinding was conducted in randomized controlled trials (RCTs) investigating medications for ADHD. We analyzed 161 double-blind RCTs of ADHD medications. We found only 1 RCT in which participants' awareness of study arm allocation was assessed and reported. Our findings are not meant to invalidate the evidence on the benefits of ADHD medications, which is supported by a large body of evidence. However, our findings suggest an opportunity to improve reporting of clinical trials in ADHD.

中文翻译：

---

系统评价： 161 项治疗注意力缺陷/多动障碍药物的随机对照试验的盲法完整性评估


我们进行了第一次系统评价，评估是否在调查 ADHD 药物的随机对照试验 （RCT） 中进行了盲法评估。我们分析了 161 项 ADHD 药物的双盲 RCT。我们发现只有 1 项 RCT 评估和报告了受试者对研究组分配的认识。我们的研究结果并不意味着 ADHD 药物益处的证据无效，这得到了大量证据的支持。然而，我们的研究结果表明有机会改进 ADHD 临床试验的报告。